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Introduction: To investigate the course of functional status assessed by health assessment questionnaire (HAQ) in
rheumatoid arthritis (RA) patients with sustained clinical remission (REM).
Methods: In recent RA clinical trials, we identified patients with subsequent visits of ≥24 weeks in clinical REM
according to the disease activity score using 28-joint counts including C-reactive protein (DAS28) (≤2.6), or
simplified disease activity index (SDAI) (≤3.3). Area under the curve (AUC) and mean HAQ scores throughout the
time in sustained REM were compared using t test, analyses of variance (ANOVA) and adjusted general linear
modeling (GLM) with repeated measures. In Cox regression analyses, the time to regain full physical function was
modeled. Sensitivity analyses were performed in patients of sustained SDAI low disease activity (LDA; SDAI ≤11).
Results: A total of 610 out of 4364 patients achieved sustained DAS28 REM (14 %) and 252 SDAI REM (5.8 %).
ANOVA testing for linear trend showed significant decrease of mean HAQ from week 0 (start of REM) to week 24,
regardless of REM criteria used. AUC of HAQ throughout 24 weeks of REM was higher in DAS28 compared to SDAI
REM (p ≤0.01). GLM adjusting for covariates showed significant decrease of monthly HAQ scores from week 0 to 24
(DAS28: 0.276, 0.243, 0.229, 0.222, 0.219, 0.209 to 0.199; p = 0.0001; SDAI: 0.147, 0.142, 0.149, 0.129, 0.123, 0.117 to
0.114; p = 0.029). Similarly, a decrease of HAQ over time was found in patients of sustained SDAI LDA. In DAS28
REM, the chance of regaining full physical function was higher for female (hazard ratio HR [95 % confidence
interval]: 1.41 [1.13–1.76]) and early RA patients (disease duration ≤2 years: HR 1.29 [1.01–1.65]); in SDAI REM no
significant differences were found.
Conclusions: Physical function continues to improve if the target of REM or LDA is sustained. The stringency of the
remission criteria determines achievement of the best possible functional improvement.Introduction
The introduction of new treatment strategies including
synthetic and biological agents has facilitated effective
management of rheumatoid arthritis (RA), leading to
better outcomes than seen in earlier years [1–5]. Clinical
remission (REM) has become a widely accepted treat-
ment goal, at least in patients with early disease, because
patients in REM show higher quality of life, better phy-
sical function and work capacity, even when compared
to low disease activity [6, 7]. Various definitions of REM
are available exerting different levels of stringency [8, 9].
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provided two new definitions of REM, showing good
predictive validity for radiographic damage and physical
function [10]. Reaching remission, however, is only the
first important goal in a targeted treatment approach,
while the maintenance of remission is yet another im-
portant subsequent step. It is evident from previous
studies that progression of joint damage decreases and
ultimately halts with increasing duration of REM [11].
Even more relevant than inhibiting structural damage is
the prevention of persistent functional disability in pa-
tients with RA. Disability affects patients’ overall well-
being at any point in time and correlates with important
long-term disease consequences, such as inability to work
or mortality [12–15]. While it had been demonstrated thatle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
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comes compared to more active disease states [7, 16], it is
unknown if functional capacity further improves or is just
sustained if the state of remission is maintained over time.
Therefore, the aim of this study was to investigate the
course of physical function in patients with sustained
clinical remission, using a large sample of patients in-
cluded in several clinical trials.
Methods
Databases
We contacted the sponsors of pivotal clinical trials in pa-
tients with RA in which newly introduced tumor necrosis
factor inhibitors (TNFi) with or without methotrexate
(MTX) or synthetic disease-modifying antirheumatic
drugs (DMARDs), in particular MTX, sulfasalazine or
leflunomide (LEF) comprised one of the treatment arms.
We were kindly provided with a random 80–90 % sample
of patients studied, including all relevant data for the
present investigation, from the baseline to the last visit of
each study (1 or 2 years) by agreement with the sponsors
including Abbvie, Amgen, Janssen, Pfizer and Sanofi and
had permission to use these data for analyses and publica-
tion of the results. These trials were: the ASPIRE trial of
infliximab plus MTX versus MTX alone in MTX-naïve
patients with early RA of 3 years or less; [17] the AT-
TRACT trial of infliximab and MTX versus placebo and
MTX in patients with inadequate prior response to MTX;
[18] the PREMIER trial on adalimumab versus MTX ver-
sus the combination of the two in patients with early RA,
who did not have previous MTX treatment; [1] the DE019
trial on adalimumab plus MTX versus placebo +MTX in
patients with inadequate response to MTX; [19] the Early
RA (ERA) trial of etanercept versus MTX; [20] the
TEMPO trial, which compared etanercept monotherapy,
etanercept plus MTX, and MTX monotherapy in patients
with established RA of 6 months to 20 years duration; [5]
and trials of leflunomide (‘LEF’ trials) comparing lefluno-
mide to sulfasalazine or MTX [21–24]. There were no sig-
nificant differences in demographic and clinical data
between the randomly provided samples and the full trial
populations.
All patients had active RA at study entry, with require-
ments for at least 6–10 swollen joints and at least 6–12
tender joints. With the exception of the ASPIRE trial,
elevations in acute phase reactants were also required
(CRP ≥1.5–2.0 mg/dL or erythrocyte sedimentation rate,
ESR, ≥28 mm/h). Functional scores based on the health
assessment questionnaire (HAQ) disability index were
available in all trials at multiple time points. Patient
demographics have been presented in the respective
publications. Ethical approval was obtained for each in-
dividual study, as referenced in the respective publica-
tions, by the institutional review board at each studycenter and the studies were carried out in accordance
with the Helsinki Declaration.
Outcome variables
Separately for each trial dataset, we identified all study
visits with available measurements of the simplified
disease activity index (SDAI), the disease activity score
using 28-joint counts including C-reactive protein
(DAS28), as well as HAQ scores. For each patient, re-
gardless of treatment arm, we investigated the presence
of REM at all study visits by applying the respective cut-
points (SDAI ≤3.3 or DAS28 ≤ 2.6). As patients can
move in and out of a state of REM over time, we next
identified all connected (subsequent) visits in REM to
identify sustained REM periods. If a composite measure
of disease activity was missing for one observation be-
tween two observed visits in REM, we assumed that the
patient had also been in REM at the missing visit. If it
was missing for more than one visit in the course of
follow-up, then the respective remission period was not
considered to be further sustained. Then, for each pa-
tient we obtained HAQ scores from the longest period
in REM, which was not necessarily the first period in
REM. We labeled the first visit of that period as week 0
of the respective remission segment; all subsequent visits
were related to that baseline in weeks. In this way we
could summarize REM periods of different patients even
if they occurred at different time points during the tri-
al(s). Only patients with at least three subsequent visits
in REM over a period of at least 24 weeks throughout
the course of the trials were used for further analyses of
their HAQ score changes. Since the underlying trials
had different visit intervals, we interpolated, if needed,
HAQ scores of each patient for weeks 0, 4, 8, 12, 16, 20,
and 24. This was done to allow us to depict the courses
of HAQ in sustained remission across a large group of
patients.
Statistical analyses
To assess the course of physical function over time in
sustained REM, we calculated mean monthly HAQ
scores and compared them across time, using analyses
of variance (ANOVA) testing for linear trend. Further-
more, the area under the curve (AUC) of HAQ scores
over time in sustained remission was calculated. All
analyses were performed separately for patients in early
(disease duration ≤2 years) and established (disease
duration >2 years) RA. Individuals regaining full physical
function (defined as HAQ = 0) were identified and their
proportion was plotted over time in sustained REM.
To adjust for factors associated with physical function,
we extended ANOVA to general linear models (GLM)
with repeated measures, using HAQ as dependent vari-
able. Covariates included in the model were: age, disease
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[RF]), radiographic damage (modified total Sharp score
[mTSS]), time from randomization to first visit in sus-
tained remission, HAQ, SDAI or DAS28 at the onset of
sustained REM, and change of disease activity (SDAI or
DAS28) from week 0 to week 24 in sustained REM. To
account for treatment regimes, patients were grouped
according to the drug regimen (synthetic DMARD
monotherapy: MTX, LEF or sulfasalazine; TNFi mono-
therapy: adalimumab or etanercept; TNFi combination
therapy with a synthetic DMARD: adalimumab, etaner-
cept, or infliximab plus MTX), and the treatment group-
ing variable was included in the model. Estimated
marginal means (EMM) were calculated, by setting the
continuous covariates to their cohort means.
Hypothesizing that physical function would also con-
tinue to improve if patients were in sustained low disease
activity (LDA), we performed a sensitivity analysis in a sub-
group of DAS28 REM patients who were in sustained
SDAI LDA (SDAI ≤11) throughout the observation period.Table 1 Patient characteristics at study entry: overall patient cohort
24 weeks or longer according to the DAS28 (second column) or SDA
Total cohort DAS28 REM SDAI
Total number of patients (%) 4364 610 (14.0 %) 252 (
Female (%) 73.90 % 64.5 % 62.3
Ethnicity (white %) 76.5 % 75.5 % 85.3
Age (years) 52.9 ± 12.8 49.8 ± 13.5 49.5 ±
Disease duration (years) 4.1 ± 6.0 2.5 ± 4.1 1.6 ±
Rheumatoid factor pos (%) 74.5 % 74.9 % 78.2
Disease activity score using 28-joint
counts including CRP (DAS28)
6.5 ± 1.1 5.53 ± 1.1 5.6 ±
Simplified disease activity index (SDAI) 44.1 ± 14.9 37.6 ± 14.1 37.7 ±
Health assessment questionnaire (HAQ) 1.5 ± 0.65 1.24 ± 0.64 1.26 ±
Swollen joint count 28 joints (SJC28) 13.2 ± 6.3 11.2 ± 5.7 10.8 ±
Tender joint count 28 joints (TJC28) 15.4 ± 6.9 12.8 ± 6.5 12.8 ±
Visual analogue scale for pain
(VAS pain in mm)
48.2 ± 29.9 51.1 ± 24.5 50.8 ±
Patient global assessment of
disease activity (PGA in mm)
61.1 ± 22.0 54.3 ± 23.8 52.8 ±
Evaluator global assessment of
disease activity (EGA in mm)
62.3 ± 18.0 57.5 ± 20.0 58.1 ±
C-reactive protein (CRP) 3.2 ± 3.8 2.6 ± 3.1 2.8 ±
Radiographic damage
(modified Sharp score)
28.8 ± 42.1 18.3 ± 26.3 15.3 ±
Treatment regime (%)
Synthetic DMARD monotherapy 40.4 % 25.4 % 20.2
TNFi monotherapy 37.5 % 43.0 % 46.8
TNFi combination therapy 20.6 % 31.6 % 32.9
Values are given for means ± standard deviation, unless indicated otherwise; p valu
in DAS28 REM or SDAI REM and comparing patients in DAS28 REM and SDAI REM.
necrosis factor inhibitorIn Cox regression analyses the time to regain full phys-
ical function, defined by achievement and sustainment
of HAQ = 0, was modeled. Covariates as described above
were entered stepwise in the model; variables with a sig-
nificance level higher than 0.1 were removed, as they did
not contribute to the model. In supplementary analyses
we also looked at the achievement of good physical




The cohort studied comprised 4364 patients with RA;
throughout the follow-up of these patients, 610 of them
(14.0 %) had a period of sustained remission of at least
24 weeks defined by DAS28, and 252 patients (5.8 %)
had sustained REM as defined by SDAI. Baseline charac-
teristics of all patients at randomization of the total co-
hort as well as of patients identified as in sustained REM
by the DAS28 or by the SDAI are depicted in Table 1.(first column), patients in sustained clinical remission of
I definition (last column) of remission
REM p value total cohort
vs. DAS28 REM
p value total cohort
vs. SDAI REM
p value DAS28 REM
vs. DAS28 REM5.8 %)
% <0.01 <0.01 0.56
% 0.37 0.20 0.52
13.2 <0.01 <0.01 0.81
2.8 <0.01 <0.01 0.01
% 0.88 0.20 0.3
1.0 <0.01 <0.01 0.73
13.8 <0.01 <0.01 0.97
0.63 <0.01 <0.01 0.72
5.2 <0.01 <0.01 0.39
5.9 <0.01 <0.01 0.88
24.0 0.02 0.18 0.87
25.2 <0.01 <0.01 0.41
20.0 <0.01 <0.01 0.76
3.3 <0.01 0.14 0.29
20.7 <0.01 <0.01 0.11
% <0.01 <0.01 0.11
% 0.01 <0.01 0.33
% <0.01 <0.01 0.75
es were obtained by comparing characteristics of the total cohort with patients
REM remission, DMARD disease-modifying antirheumatic drugs, TNFi tumor
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of disease activity, higher frequencies of RF, and shorter
duration of RA (p <0.05 for all) compared to the total
study population. No significant differences of baseline
characteristics were found between patients achieving
sustained DAS28 and those in SDAI REM, except that
patients achieving SDAI REM had significantly shorter
duration of RA (p = 0.001; Table 1). Disease activity vari-
ables at the start of sustained DAS28 and SDAI REM
are shown in Table 2. Mean HAQ scores as well as other
measures of disease activity at the start of sustained
SDAI REM were significantly lower than those at the
start of sustained DAS28 REM (p <0.01 for all variables
except CRP). On average, the first period of sustained
REM defined by DAS28 started at 26.2 ± 20.2 weeks
after randomization, while sustained REM according to
SDAI started at 31.2 ± 22.1 weeks (p = 0.004). Over the
time in sustained REM defined by DAS28, an increas-
ing proportion of these patients also achieved SDAI
REM (41.8 % at the start of sustained DAS28 REM and
59.2 % at week 24 of sustained DAS28 REM); indepen-
dent of the definition of REM, all measures of disease
activity except CRP decreased significantly from week 0
to week 24 in sustained remission, (p <0.01 for all vari-
ables; Table 2).
Unadjusted analyses of functional course in sustained
remission
Using ANOVA we found a significant improvement
of HAQ scores over time in sustained DAS28 REM
(p <0.001; testing for linear trend) of 28.6 % from a mean
of 0.28 ± 0.4 at onset of the remission period (week 0) to
0.20 ± 0.3 after 24 weeks (Fig. 1a; blue line). In SDAI REM
we also found a significant linear trend (p = 0.04). MeanTable 2 Patients characteristics at first visit and week 24 in sustained
24 weeks or longer according to the DAS28 and SDAI definition of r
DAS28 REM
Week 0 Week 24
Disease activity score using 28-joint
counts including CRP (DAS28)
2.1 ± 0.3 (1.21–2.6) 1.9 ± 0.3 (1.01
Simplified disease activity index (SDAI) 4.3 ± 2.8 (0.3–16.1) 3.2 ± 2.5 (0.1–
Health assessment questionnaire (HAQ) 0.28 ± 0.4 (0–2.25) 0.20 ± 0.4 (0–
Swollen joint count 28 joints (SJC28) 1.3 ± 2.2 (0–15) 0.8 ± 2.0 (0–1
Tender joint count 28 joints (TJC28) 0.4 ± 0.7 (0–3) 0.2 ± 0.5 (0–3
Visual analogue scale for pain
(VAS pain in mm)
8.8 ± 10.9 (0–80) 6.9 ± 8.5 (0–6
Patient global assessment of disease
activity (PGA in mm)
11 ± 11.8 (0–70) 8.8 ± 9.6 (0–5
Evaluator global assessment of disease
activity (EGA in mm)
10.2 ± 10.3 (0–92) 7.7 ± 8.9 (0–9
C-reactive protein (CRP, mg/dL) 0.50 ± 0.6 (0.1–9.4) 0.52 ± 0.5 (0.1
Values are given for means ± standard deviation, significant differences were detect
between DAS28 REM and SDAI REM were significant at p <0.01 for all variables andHAQ scores were significantly lower in SDAI REM com-
pared to DAS28 REM with significantly lower AUC of
HAQ in SDAI REM compared to DAS28 REM (p <0.001;
Fig. 1a). In fact, after 24 weeks of sustained DAS28 REM,
HAQ scores were on average still higher (0.20 ± 0.4) than
they had already been at the onset of SDAI-based REM
(week 0: 0.15 ± 0.3). When we split patients according to
their disease duration, those with early RA in DAS28
REM had significantly lower AUC of HAQ compared to
those with established RA (p <0.001; Fig. 1b). There was a
significant decrease of HAQ over time for both groups
(Fig. 1b; ANOVA testing for linear trend: p = 0.004 for
early RA; p = 0.001 for established RA). For SDAI REM,
no significant differences of AUC of HAQ between early
and established RA were found (p = 0.22). In addition, no
significant change of mean HAQ scores over time in SDAI
REM were seen within the early and established RA
groups (Fig. 1c; ANOVA testing for linear trend: p = 0.21
and p = 0.06 respectively). However, the mean HAQ
scores at the start of sustained SDAI REM were already
quite low irrespective of disease duration, leaving little
room for further statistically significant improvement until
week 24.
In sensitivity analyses we looked at the course of func-
tion in patients with complete data without interpolation
of HAQ showing similar results and a decrease of HAQ
over time in remission (Figure S1 in Additional file 1).
Adjusted analyses of the course of physical function in
sustained remission
After adjusting for covariates in GLM repeated mea-
sures, we found a significant change of HAQ scores over
time in patients with sustained DAS28 REM (p = 0.02).
Mean HAQ scores estimated for each time point duringremission for patients in sustained clinical remission of
emission
SDAI REM
p Week 0 Week 24 p
–2.59) P <0.01 1.8 ± 0.28 (1.21–2.72) 1.7 ± 0.2 (1.21–2.72) P <0.01
18.2) P <0.01 1.9 ± 0.9 (0.1–3.3) 1.3 ± 0.8 (0.1–3.24) P <0.01
1.92) P <0.01 0.15 ± 0.3 (0–2.25) 0.11 ± 0.3 (0–1.75) P <0.01
7) P <0.01 0.3 ± 0.5 (0–2) 0.2 ± 0.4 (0–2) P <0.01
) P <0.01 0.2 ± 0.5 (0–2) 0.1 ± 0.4 (0–2) P <0.01
4) P <0.01 4.4 ± 6.1 (0–53) 3.0 ± 4.0 (0–24) P <0.01
7) P <0.01 4.5 ± 5.4 (0–27) 3.5 ± 4.9 (0–30) P <0.01
3) P <0.01 4.4 ± 4.7 (0–24) 3.1 ± 3.7 (0–17) P <0.01
–4.3) P = 0.46 0.49 ± 0.4 (0.1–2.92) 0.50 ± 0.4 (0.1–3.8) P = 0.69
ed, using Student’s t test. Values in parentheses depict ranges. Differences
time points except for CRP. REM remission
Fig. 1 Unadjusted analyses of variance (ANOVA): a mean values of health assessment questionnaire (HAQ) plotted over time in sustained clinical
remission defined by DAS28 (blue line) or SDAI (red line) showing a decrease over time. Stratification of the cohort in early (disease duration ≤2 years,
full line) and established RA patients (dotted line) in sustained remission defined by (b) DAS28 or (c) SDAI (p values testing for linear trend; asterisk
indicates significance). DAS28 disease activity score using 28-joint counts including CRP, RA rheumatoid arthritis, SDAI simplified disease activity index
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0 to week 24 (0.276, 0.243, 0.229, 0.222, 0.219, 0.209 to
0.199 at 4-weekly assessments; p <0.01; i.e., a further im-
provement of 28.7 %; Fig. 2a, black line). Similar results
were obtained when defining REM using SDAI-based
REM: mean HAQ scores were 0.147, 0.142, 0.149, 0.129,
0.123, 0.117, and 0.114, respectively, for the different time
points; i.e., a further improvement of 23.1 %; p = 0.029;
Fig. 2a red line). Using either REM criteria, no significant
effect of disease duration (early RA ≤2 years versus estab-
lished RA >2 years) was found (Fig. 2, panel b DAS28
REM p = 0.57; panel c SDAI REM p = 0.70).
In a sensitivity analysis we looked at a subgroup of pa-
tients in DAS28 REM who were in sustained SDAI LDA
(n = 159) over 24 weeks. We found a similar significant
decrease of mean HAQ over time in sustained SDAI LDA
in unadjusted ANOVA (testing for linear trend p <0.001)and GLM adjusting for covariates (Figure S2 in Additional
file 2).
Achievement of full physical function during sustained
remission
Over time in sustained REM, 57.7 % of the patients in
DAS28 REM regained full physical function (HAQ = 0).
This proportion was significantly higher in patients with
sustained SDAI REM (72.6 %, p <0.001). The percentage
of patients regaining full physical function is depicted in
Fig. 3a, separately for patients in DAS28 and SDAI
REM.
In a Cox regression model predicting recovery of full
physical function over time in sustained REM, we in-
cluded additional explanatory variables. In DAS28 REM
the hazard ratio (HR; 95 % confidence intervals [CIs])
for regaining full physical function was 1.41 (1.13–1.76)
Fig. 2 Physical disability decreases over time in sustained remission after adjusting for covariates. a For the DAS28 (blue line), the graphs depict
the means of the health assessment questionnaire (HAQ) considering all covariates, i.e., estimating for a female, seropositive patient at age
49.6 years, disease duration of 2.4 years, time to sustained REM of 26.8 weeks, a change of DAS28 from week 0 to week 24 in REM of 0.17, and a
DAS28 of 2.07 and a HAQ of 0.28 at first REM visit, as well as a modified total Sharp score (mTSS) of 18.35; for the SDAI (red line) the means were
estimated for a female, seropositive patient at age 49.6, with a disease duration of 1.5 years, a time to sustained REM of 31.7 weeks, a change of
SDAI from week 0 to week 24 in REM of 0.54, and an SDAI of 1.87 and HAQ of 0.15 at the first REM visit, as well as a mTSS Sharp score of 15.55.
Mean as estimated separately for early RA (disease duration ≤2 years; dotted line) and established RA (disease duration >2 years; full line) patients
in (b) DAS28 REM and (c) SDAI REM showed a significant decrease of HAQ scores over time in sustained REM, but no differences between early and
established RA patients. DAS28 disease activity score using 28-joint counts including CRP, RA rheumatoid arthritis, REM remission, SDAI simplified disease
activity index
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1.29 (1.01–1.65) times higher for early RA patients com-
pared to those with established RA (Table 3, left column;
Fig. 3, panel b). For patients in sustained SDAI REM,
only age significantly contributed to the model, with
decreasing HR of regaining full physical function with
increasing age (HR 0.98; 95 % CI 0.97–0.99; (Table 3,
right column; Fig. 2, panel c). In DAS28 as well as SDAI
REM treatment regimen and seropositivity were found
to not significantly contribute to the achievement of full
physical function and therefore were excluded from the
final models.In sensitivity analyses we also looked at the recuper-
ation of good physical function (HAQ ≤0.5), showing
again statistically higher percentages in patients with
SDAI REM compared to DAS28 REM (93.3 % versus
85.6 %, p = 0.001; Figure S3 panel A in Additional file 3).
When dividing patients into subgroups by disease dur-
ation, 90.4 % of early RA patients achieving SDAI REM
regained good physical function already at week 0 of
REM compared to 80.8 % with established disease
(Figure S3 panel B in Additional file 3). After adjusting
for covariates in Cox regression analyses predicting good
function, no differences in HR between early and late
Fig. 3 Recovery of full physical function (HAQ = 0) during the time in sustained remission. a Unadjusted analyses: percentage (95 % confidence
interval) of patients regaining full physical function in REM defined by DAS28 (blue line) and SDAI (red line). Adjusted Cox regression analyses
adjusted for age, gender, radiographic damage, disease duration, disease activity at week 0 in REM, change of disease activity from week 0 to
week 24 in REM, and time from randomization until sustained REM. Survival curves were plotted separately for (b) DAS28 and (c) SDAI REM.
DAS28 disease activity score using 28-joint counts including CRP, HAQ health assessment questionnaire, REM remission, SDAI simplified disease
activity index
Table 3 Cox regression to model the time to regain full physical function, defined by a sustained health assessment questionnaire
(HAQ) score of zero within time in sustained remission
Variables included in the model DAS28 remission SDAI remission
HR 95 % CI Sig HR 95 % CI Sig
Age (years) 0.98 0.97–0.99 <0.01 0.98 0.97–0.99 0.01
Early RA (≤2 years disease duration) 1.29 1.01–1.65 0.049 Removed from final model
Gender (female) 1.41 1.13–1.76 0.002 Removed from final model
Time from randomization until sustained
remission (weeks)
0.99 0.98–0.99 0.014 Removed from final model
DAS28/SDAI at week 0 in sustained remission 0.36 0.23–0.57 <0.01 Removed from final model
Change DAS28/SDAI from week 0 to week 24
in sustained remission
1.67 1.16–2.40 0.006 Removed from final model
Table depicts hazard ratios (HR) and 95 % confidence interval (95 % CI) of all covariates included in the model, separately for patients in sustained DAS28 and
SDAI defined remission. DAS28 disease activity score using 28-joint counts including CRP, SDAI simplified disease activity index, HR hazard ratio, CI confidence
interval, RA rheumatoid arthritis
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REM (Figure S3 panel C and D in Additional file 3).
Discussion
In our study we were able to show that physical function
continues to improve over time when remission is main-
tained. Thus, improvement of physical function does not
reach a maximum extent with the first achievement of a
good clinical state, but only with maintenance of this
condition. This is reminiscent of data showing that halt
of joint damage depends on maintenance of a good clin-
ical outcome such as REM [26]. For joint damage it was
implied that, despite overall reduction in progression
rates already at the time when REM was first achieved,
there was still a carry-over effect of destructive mecha-
nisms beyond this time point of an initial REM state
[11]. Along similar lines, one may conclude that func-
tional limitations that were a consequence of the disease
process also need time to recover after the disease
process has subsided on therapy.
The other finding is the fact that the stringency of the
REM definition itself not only determines the functional
state of those reaching REM, but also – as a consequence –
the degree of further functional improvement if REM is
sustained. This is apparent when comparing the functional
courses of patients in DAS28 REM and SDAI REM: it is
well known that most core set variables are significantly
higher at the onset of DAS28 REM, than as the stringent
SDAI REM; this apparently has led to the fact that HAQ
scores in REM were not only higher in DAS28 REM, but
also HAQ improvement in sustained REM was more
clearly seen when using the DAS28 < 2.6 definition than
the SDAI definition. HAQ scores at the time of the initial
visit in SDAI REM had already reached a mean value of
0.15. Thus, the stringency of REM criteria determines the
extent of recovery of physical ability, and the more strin-
gent the criteria, the larger the extent of functional im-
provement which had already taken place during the time
before reaching that state. Indeed, with maintenance of
REM, whichever way defined, there is also continuing im-
provement of the respective disease activity scores so that
after 6 months of sustained REM the mean values of most
individual disease activity measures are significantly lower
than at the start of the sustained REM period. A sensitivity
analysis performed in patients with sustained SDAI LDA
underlines the association of simply maintaining a low dis-
ease activity state as an alternative good treatment out-
come with improvement of physical function over time.
Previous studies have suggested an association be-
tween time in REM and functional or radiographic out-
comes; [11, 16] the shorter the period of REM, the more
likely some radiographic progression was present. Joint
damage can serve as a surrogate marker for irreversible
impairment of physical function [27, 28]. Furthermore,also the level of disease activity in REM is important. Even
when already reaching REM, depending on the definition
of REM, residual joint inflammation might be observed,
which could be an explanation for structural deterioration
in RA patients [29, 30]. Indeed, in our cohort, patients in
REM defined by DAS28 showed up to 17 swollen joints,
compared to patients in SDAI REM, where a maximum of
two swollen joints was present. Thus, the more stringent
the REM criteria are, the higher the chance for good func-
tional and structural outcomes, as less clinical abnor-
malities are present and fewer subclinical pathologies are
detectable [31]. However, it must be borne in mind that
structural progression in REM by any means is relatively
small, and that other factors contribute to the observable
improvement in function. Even after adjusting for covari-
ates such as age, disease duration or radiographic damage,
and finally also disease activity itself (which also decreased
in sustained remission) such improvement in physical
function was observed. Several explanations for this phe-
nomenon come to mind. First, it is likely that mobility of
previously inflamed joints, muscle wasting related to dis-
ease activity, and systemic features, such as fatigue and
malaise need time to fully restore after disease activity has
stopped. Second, however, it is also possible that even the
small residual disease activity in remission contributes to
some functional impairment and that the observed im-
provement of this residual disease activity over time in
sustained REM has an impact on physical function due to
the continuing decrease of the residual low degrees of pain
and tenderness. The significantly better physical function
in sustained SDAI-defined REM compared to DAS28 is
well in line with this notion.
In our study we found an average improvement of
HAQ of 0.08 within 24 weeks of sustained DAS28 REM
or respective 0.04 in SDAI REM. Even though these
changes may seem small in their extent, it has to be em-
phasized that patients in REM are already in very good
functional status to start with. On the group level in this
population, the relative further improvement was be-
tween a quarter and a third of the initial HAQ assess-
ment. Almost 20 % of the patients regained full physical
function within sustained REM. Also, on an individual
patient level, improvement of HAQ showed wide vari-
ability with change of HAQ of up to 2.1 in DAS REM
and 0.8 in SDAI REM, with a large number of patients
experiencing further improvement in sustained remis-
sion beyond the minimal clinically important difference
of 0.2 [32, 33]. Furthermore, as the HAQ scale shows
nonlinearity, a change from 1.6 to 1.4 may not be the
same as changes from 0.4 to 0.2. Indeed, it was shown
previously that the threshold of symptomatic difference
is smaller if patients are less disabled [34].
Several limitations of our study need to be addressed:
first, the evaluated trials had partly different visit intervals.
Radner et al. Arthritis Research & Therapy  (2015) 17:203 Page 9 of 10Since we interpolated to monthly assessments, fluctuation
of disease activity might have been missed and some pa-
tients assumed to be in sustained remission while in fact
they were not. By requiring at least three subsequent visits
in REM, and 24 weeks of observation time, it is unlikely
that this limitation applied to a significant number of pa-
tients. Second, the development of physical disability is a
multifactorial process with different aspects and causes,
some of which are RA related, while others are related to
other factors in the patient’s life such as comorbidities or
psychological status [35, 36]. Some of these factors were
not measured in our study; therefore, our analyses did not
account for them. Third, we employed DAS28, since we
had CRP available in all trials, but ESR was missing in
some of them; however, in a sensitivity analysis using
DAS28-ESR we obtained very similar results.
A strength of our study is the use of a large sample of
patients included in recent large-scale randomized con-
trolled RA clinical trials. Due to the respective inclusion
and exclusion criteria, patients were homogeneous,
which allows the best possible assessment of different
associations. Nevertheless, due to this preselected con-
ditions, generalization of findings might be limited. In
addition, the included trials were conducted before the
introduction of the new 2010 ACR/EULAR classification
criteria of RA and, therefore, our conclusions may not
be assignable to all RA populations.
Conclusions
In summary, we were able to show that physical function
continues to improve over time if a clinical target is
reached and sustained, as shown here for a state of low
disease activity or remission. The functional level at the
onset of remission, as well as the ability to improve de-
pends on the stringency of the remission criteria used.
These data call for and support the continuation of fol-
lowing a treatment goal of sustained clinical remission.
This will allow for all patients to regain their best phys-
ical function possible.
Additional files
Additional file 1: Figure S1. Unadjusted analyses of variance (ANOVA)
in patients with complete data on HAQ: mean values of the health
assessment questionnaire (HAQ) plotted over time in sustained clinical
remission (REM) defined by DAS28 (n = 132; blue line) or SDAI (n = 26; red
line) showing a decrease over time. ANOVA testing for linear trend was
significant in patients achieving DAS28 REM (p = 0.02), but not in SDAI
REM (p = 0.41). (JPEG 32 kb)
Additional file 2: Figure S2. Physical disability decreases over time in
sustained low disease activity (LDA). (A) Unadjusted analyses of variance
(ANOVA): mean values of the health assessment questionnaire (HAQ)
plotted over time in sustained LDA defined by the simplified disease activity
index (SDAI ≤11) showing a decrease over time (p <0.001 ANOVA testing
for linear trend). (B) Adjusted analyses: estimated marginal means of HAQ
considering all covariates, i.e., estimating for a female, seropositive patient atage 50.2 years, disease duration of 2.1 years, time to sustained LDA of
21.6 weeks, a change of SDAI from week 0 to week 24 of 3.2, a SDAI of 5.0
and a HAQ of 0.28 at first LDA visit, as well as a modified total Sharp score
(mTSS) of 19.6. (JPEG 46 kb)
Additional file 3: Figure S3. Regain of good physical function
(HAQ ≤0.5) during the time in sustained remission. Unadjusted analyses:
percentage (95 % confidence interval) of patients regaining good physical
function in remission defined by DAS28 (blue line) and SDAI (red line) for
(A) the total cohort and (B) separately for early RA (full line) and established
RA (dotted line). Adjusted Cox regression analyses adjusted for age, gender,
radiographic damage, disease duration, disease activity at week 0 in REM,
change of disease activity from week 0 to week 24 in REM, and time from
randomization until sustained remission plotted separately for patients in
(C) DAS28 and (D) SDAI remission. (JPEG 93 kb)
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